C5-Binding Antibodies for Complement Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for diseases associated with the complement system, particularly age-related macular degeneration, lack specific and well-tolerated targets, leading to unintended tissue damage due to non-discriminatory activation of complement products.
Innovation Solution
Development of isolated complement C5-binding molecules, such as antibodies or antigen binding fragments, with high affinity and specificity to inhibit the alternative complement pathway, thereby reducing tissue damage while targeting C5 protein.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If complement products are used to defend against infection and inflammation, then host defense function is improved, but bystander cells and tissues suffer extensive damage due to non-discriminatory activation
Solution Approach 1:
The antibody is designed to bind specifically to the C5 protein, introducing local specificity to the complement activation process. By targeting only C5 and not other complement components or host tissues, the treatment achieves localized action at the molecular level, preserving healthy tissues while neutralizing the harmful effects of unrestricted complement activation.
Solution Approach 2:
The C5-binding antibody acts as an intermediary molecule that intercepts the complement cascade at the C5 conversion step. This intermediary blocks the formation of C5a and C5b, preventing downstream formation of the membrane attack complex (MAC) and thereby protecting bystander cells and tissues from damage while allowing controlled immune response.
2Reliability
If current treatments target classical or alternative component pathways, then disease symptoms are addressed, but well-tolerated treatment is not achieved due to lack of specific targets
Solution Approach 1:
The treatment introduces local quality by specifically targeting the C5 protein rather than broadly suppressing complement pathways. This molecular-level specificity ensures that only the pathological complement activation is inhibited while preserving normal immune functions, thereby achieving effective disease treatment with improved safety profile.
Solution Approach 2:
The invention changes the parameter of treatment specificity by shifting from non-specific pathway inhibition to specific C5 protein targeting. This parameter change in molecular specificity transforms the treatment profile from one causing unintended tissue damage to one that is well-tolerated and selectively effective against disease pathology.
3Reliability
If C5 is cleaved by C5 convertase to release C5a and C5b, then inflammatory response and membrane attack complex formation occur, but unrestricted activation causes extensive damage to bystander cells and tissues
Solution Approach 1:
The C5-binding antibody performs preliminary anti-action by preemptively blocking C5 before it can be cleaved by C5 convertase. This preliminary intervention prevents the release of C5a (a potent inflammatory molecule) and C5b (which initiates MAC formation), thereby stopping the complement cascade before it can cause damage to bystander cells while still allowing controlled immune defense.
Data Source
AI summary
The present invention relates to antibodies targeting complement protein C5 and compositions and methods of use thereof.